Inhibiting Glycogen Synthesis Prevents Lafora Disease in a Mouse Model

被引:70
|
作者
Pederson, Bartholomew A. [1 ]
Turnbull, Julie [2 ]
Epp, Jonathan R. [3 ]
Weaver, Staci A. [1 ]
Zhao, Xiaochu [2 ]
Pencea, Nela [2 ,4 ]
Roach, Peter J. [5 ]
Frankland, Paul W. [3 ]
Ackerley, Cameron A. [1 ]
Minassian, Berge A. [2 ,6 ,7 ]
机构
[1] Ball State Univ, Indiana Univ, Sch Med Muncie, Muncie, IN 47306 USA
[2] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada
[3] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada
[4] Hosp Sick Children, Div Pathol, Dept Pathol & Lab Med, Toronto, ON M5G 1X8, Canada
[5] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA
[6] Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON M5G 1X8, Canada
[7] Univ Toronto, Toronto, ON M5S 1A1, Canada
基金
加拿大健康研究院;
关键词
MYOCLONUS EPILEPSY; UBIQUITIN LIGASE; MUSCLE GLYCOGEN; MALIN; DEGRADATION; SYNTHASE; MICE; NEURODEGENERATION; METABOLISM; EXERCISE;
D O I
10.1002/ana.23899
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Lafora disease (LD) is a fatal progressive myoclonus epilepsy characterized neuropathologically by aggregates of abnormally structured glycogen and proteins (Lafora bodies [LBs]), and neurodegeneration. Whether LBs could be prevented by inhibiting glycogen synthesis and whether they are pathogenic remain uncertain. We genetically eliminated brain glycogen synthesis in LD mice. This resulted in long-term prevention of LB formation, neurodegeneration, and seizure susceptibility. This study establishes that glycogen synthesis is requisite for LB formation and that LBs are pathogenic. It opens a therapeutic window for potential treatments in LD with known and future small molecule inhibitors of glycogen synthesis.
引用
收藏
页码:297 / 300
页数:4
相关论文
共 50 条
  • [1] Glycogen metabolism in tissues from a mouse model of Lafora disease
    Wang, Wei
    Lohi, Hannes
    Skurat, Alexander V.
    DePaoli-Roach, Anna A.
    Minassian, Berge A.
    Roach, Peter J.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2007, 457 (02) : 264 - 269
  • [2] Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora disease
    Valles-Ortega, Jordi
    Duran, Jordi
    Garcia-Rocha, Mar
    Bosch, Carles
    Saez, Isabel
    Pujadas, Lluis
    Serafin, Anna
    Canas, Xavier
    Soriano, Eduardo
    Delgado-Garcia, Jose M.
    Gruart, Agnes
    Guinovart, Joan J.
    EMBO MOLECULAR MEDICINE, 2011, 3 (11) : 667 - 681
  • [3] Phosphate Incorporation during Glycogen Synthesis and Lafora Disease
    Tagliabracci, Vincent S.
    Heiss, Christian
    Karthik, Chandra
    Contreras, Christopher J.
    Glushka, John
    Ishihara, Mayumi
    Azadi, Parastoo
    Hurley, Thomas D.
    DePaoli-Roach, Anna A.
    Roach, Peter J.
    CELL METABOLISM, 2011, 13 (03) : 274 - 282
  • [4] Glycogen phosphorylation and Lafora disease
    Roach, Peter J.
    MOLECULAR ASPECTS OF MEDICINE, 2015, 46 : 78 - 84
  • [5] Glycogen Phosphomonoester Distribution in Mouse Models of the Progressive Myoclonic Epilepsy, Lafora Disease
    DePaoli-Roach, Anna A.
    Contreras, Christopher J.
    Segvich, Dyann M.
    Heiss, Christian
    Ishihara, Mayumi
    Azadi, Parastoo
    Roach, Peter J.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (02) : 841 - 850
  • [6] Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity
    Varea, Olga
    Duran, Jordi
    Aguilera, Monica
    Prats, Neus
    Guinovart, Joan J.
    NEUROBIOLOGY OF DISEASE, 2021, 147
  • [7] Effects of Lafora disease on the retina of a transgenic mouse model
    Campbell, Melanie C. W.
    Emptage, Laura
    Corapi, Frank
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [8] Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model
    Katherine J. Donohue
    Bethany Fitzsimmons
    Ronald C. Bruntz
    Kia H. Markussen
    Lyndsay E. A. Young
    Harrison A. Clarke
    Peyton T. Coburn
    Laiken E. Griffith
    William Sanders
    Jack Klier
    Sara N. Burke
    Andrew P. Maurer
    Berge A. Minassian
    Ramon C. Sun
    Holly B. Kordasiewisz
    Matthew S. Gentry
    Neurotherapeutics, 2023, 20 : 1808 - 1819
  • [9] Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model
    Donohue, Katherine J.
    Fitzsimmons, Bethany
    Bruntz, Ronald C.
    Markussen, Kia H.
    Young, Lyndsay E. A.
    Clarke, Harrison A.
    Coburn, Peyton T.
    Griffith, Laiken E.
    Sanders, William
    Klier, Jack
    Burke, Sara N.
    Maurer, Andrew P.
    Minassian, Berge A.
    Sun, Ramon C.
    Kordasiewisz, Holly B.
    Gentry, Matthew S.
    NEUROTHERAPEUTICS, 2023, 20 (06) : 1808 - 1819
  • [10] In vivo glutamate clearance defects in a mouse model of Lafora disease
    Munoz-Ballester, C.
    Santana, N.
    Perez-Jimenez, E.
    Viana, R.
    Artigas, F.
    Sanz, P.
    EXPERIMENTAL NEUROLOGY, 2019, 320